2008
DOI: 10.1111/j.1600-0463.2008.00999.x
|View full text |Cite
|
Sign up to set email alerts
|

Expression of NEDD‐1, a PTEN regulator, in gastric and colorectal carcinomas

Abstract: Recent studies have disclosed that NEDD4-1 regulates PTEN activity by ubiquitination. NEDD4-1 negatively regulates PTEN in cytosol and acts as an oncogenic protein. By contrast, NEDD4-1 promotes PTEN nuclear import and acts as a tumor suppressor. Despite the importance of NEDD4-1 in PTEN regulation in cancer cells, expression of NEDD4-1 protein in cancer tissues is unknown. The aim of this study was to analyze NEDD4-1 expression in colorectal and gastric cancer tissues. We investigated NEDD4-1 protein expressi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
46
0

Year Published

2010
2010
2019
2019

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 56 publications
(48 citation statements)
references
References 16 publications
2
46
0
Order By: Relevance
“…Interestingly, as in previous studies with various cancer cells (30,49), we observed an inverse correlation between PTEN and NEDD4-1 protein levels upon zinc treatment in mouse brains (Fig. 7).…”
Section: Discussionsupporting
confidence: 71%
“…Interestingly, as in previous studies with various cancer cells (30,49), we observed an inverse correlation between PTEN and NEDD4-1 protein levels upon zinc treatment in mouse brains (Fig. 7).…”
Section: Discussionsupporting
confidence: 71%
“…To our knowledge this is the first thorough study of NEDD4-1 expression in human cancer with a significant correlation with PTEN status: NEDD4-1 overexpression has been reported in limited cohorts of patients with urinary bladder (mRNA) and gastrointestinal (protein) cancers. 24,35 The TMA immunostaining studies reported in this article demonstrated that most NSCLC overexpress NEDD4-1 compared with normal lung epithelium, implying that the acquisition of NEDD4-1 expression might represent an oncogenic event during cancer development in the lung. The observation that there is no significant difference in NEDD4-1 levels with respect to histological subtypes, grade, stage, or metastasis, suggests that enhanced NEDD4-1 expression might occur at an early stage of the tumorigenic process.…”
Section: Discussionmentioning
confidence: 99%
“…33,34 The antibody used in immunostaining of TMAs for NEDD4-1 (number 07-049, Upstate Biotechnology, Lake Placid, NY) had been developed by immunizing rabbit with a synthetic peptide of the NEDD4-1WW domain and its specificity was described in a previous study on colon and gastric cancer. 35 The specificity of the antibodies used in our study was assessed by three control experiments: absence of consistent immunostaining of cells when the anti-NEDD4-1 or anti-PTEN antibodies were replaced with normal rabbit serum at the same dilution; progressive reduction of signal intensity as dilution of the antibody was increased; and abrogation of signal after pre-incubation with the immunizing peptide.…”
Section: Immunohistochemistrymentioning
confidence: 99%
“…The Nedd4-IRS-2 binding may represent a novel drug target at least in prostate cancer. Accumulating evidence suggests that Nedd4 is overexpressed in various cancers and functions as a tumour-promoting factor [17][18][19][20][21] . It is important to investigate the contribution of the Nedd4-IRS-2 complex to the development of various cancers.…”
Section: Discussionmentioning
confidence: 99%
“…Nedd4 knockout mice show fetal growth retardation and perinatal lethality 16 , indicating a crucial role for Nedd4 in embryonic growth. Nedd4 is overexpressed in several types of cancers and functions as an oncogenic protein [17][18][19][20][21] . We provide multiple lines of evidence, suggesting that Nedd4 conjugates monoubiquitin to IRS-2 and recruits IRS-2 to the plasma membrane, thereby enhancing IRS-2 tyrosine phosphorylation by IGF-IR and IGF-I mitogenic activity.…”
mentioning
confidence: 99%